Trending...
- Awake! Ye Sisters All: Sisterhood in Boston's Women's Voter Registers
- Boston: Inaugural Cohort of Young Black Leaders Announced
- See what our March partners are offering now!
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene today announced that four abstracts have been accepted for poster presentations for the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held December 6 - 9, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 107.
"The data we will present at SABCS demonstrates the clinical utility of BostonGene's AI-based molecular and immune profiling and analytics to advance and optimize outcomes for cancer patients," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings highlight the importance of a multifaceted approach to understand the composition and activity of the tumor and the microenvironment."
Details about the abstracts selected for presentation can be found below:
Abstract Number: 1304759
Title: A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Date and Time: Thursday, December 8 | 7:00 AM - 8:15 AM
Location: Poster Session 4 – Hall 1
Poster Number: P4-09-02
Speaker: Nikita Kotlov, BostonGene
Using whole-transcriptome data clustering techniques, BostonGene uncovered five distinct basal-like breast cancer molecular functional portraits prognostic for survival using gene signatures from the tumor microenvironment.
Abstract Number: 1310282
Title: An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response
More on Boston Chron
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-45
Speaker: Nikita Kotlov, BostonGene
BostonGene developed and validated a new homologous recombination deficiency (HRD) scoring system for breast cancer patients. This novel HRD score, which uses long-focal copy number alterations and ploidy rather than relying on germline mutations in the homologous recombination pathway, was predictive of PARP inhibitor response.
Abstract Number: 1310386
Title: AI-based prediction of tertiary lymphoid structures and lymphocyte immune infiltration in breast carcinomas
Date and Time: Friday, December 9 | 7:00 AM - 8:15 AM
Location: Poster Session 6 – Hall 1
Poster Number: P6-04-15
Speaker: Ekaterina Postovalova, PhD, BostonGene
Leveraging a convolutional neural network, BostonGene trained and validated an image analysis platform capable of detecting tertiary lymphoid structures and the lymphocyte immune-infiltrated area on breast carcinoma H&E slides. This AI-based approach may be used to automate the traditional pathology workflow.
Abstract Number: 1310481
Title: TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-13
Speaker: Jennifer C. Keenan, Mass General Cancer Center
More on Boston Chron
In this case report, BostonGene's Tumor Portrait™ next-generation sequencing test provided orthogonal validation for two NTRK fusions, including one novel fusion, detected by cell-free DNA analysis in a metastatic triple-negative breast cancer patient.
Research conducted with Mass General Cancer Center
For more information, please visit the 2022 San Antonio Breast Cancer Symposium website. The abstracts will be published in the Abstracts2View™ online database at the conclusion of the symposium.
About BostonGene Corporation
BostonGene's mission is to power healthcare's transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
Contacts
Media:
BostonGene
Erin O'Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com
"The data we will present at SABCS demonstrates the clinical utility of BostonGene's AI-based molecular and immune profiling and analytics to advance and optimize outcomes for cancer patients," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings highlight the importance of a multifaceted approach to understand the composition and activity of the tumor and the microenvironment."
Details about the abstracts selected for presentation can be found below:
Abstract Number: 1304759
Title: A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Date and Time: Thursday, December 8 | 7:00 AM - 8:15 AM
Location: Poster Session 4 – Hall 1
Poster Number: P4-09-02
Speaker: Nikita Kotlov, BostonGene
Using whole-transcriptome data clustering techniques, BostonGene uncovered five distinct basal-like breast cancer molecular functional portraits prognostic for survival using gene signatures from the tumor microenvironment.
Abstract Number: 1310282
Title: An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response
More on Boston Chron
- Boston: March 2023: Latest Updates from the Mayor's Office of Housing
- Boston: April Allston/Brighton Community Center Study Meeting
- Boston: Mayor Wu Launches $750,000 Grant Fund to Support Growth of Businesses and Access to City Contracts
- Mayor Wu Announces $4 Million Investment to Expand Boston's Tuition Free Community College Program
- Boston: Meet the Fine Arts Work Center Scholarship Recipients
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-45
Speaker: Nikita Kotlov, BostonGene
BostonGene developed and validated a new homologous recombination deficiency (HRD) scoring system for breast cancer patients. This novel HRD score, which uses long-focal copy number alterations and ploidy rather than relying on germline mutations in the homologous recombination pathway, was predictive of PARP inhibitor response.
Abstract Number: 1310386
Title: AI-based prediction of tertiary lymphoid structures and lymphocyte immune infiltration in breast carcinomas
Date and Time: Friday, December 9 | 7:00 AM - 8:15 AM
Location: Poster Session 6 – Hall 1
Poster Number: P6-04-15
Speaker: Ekaterina Postovalova, PhD, BostonGene
Leveraging a convolutional neural network, BostonGene trained and validated an image analysis platform capable of detecting tertiary lymphoid structures and the lymphocyte immune-infiltrated area on breast carcinoma H&E slides. This AI-based approach may be used to automate the traditional pathology workflow.
Abstract Number: 1310481
Title: TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-13
Speaker: Jennifer C. Keenan, Mass General Cancer Center
More on Boston Chron
- Boston: The Mary Eliza Project: Ward 3 Voter Records Now Available
- Boston AIR Spotlight: Ellice Patterson and Boston Transportation Department
- Mayor Wu Announces Applications Open for the 2023-2024 SPARK Boston Council
- Awake! Ye Sisters All: Sisterhood in Boston's Women's Voter Registers
- Mayor Wu Announces Events in Remembrance of the 2013 Boston Marathon
In this case report, BostonGene's Tumor Portrait™ next-generation sequencing test provided orthogonal validation for two NTRK fusions, including one novel fusion, detected by cell-free DNA analysis in a metastatic triple-negative breast cancer patient.
Research conducted with Mass General Cancer Center
For more information, please visit the 2022 San Antonio Breast Cancer Symposium website. The abstracts will be published in the Abstracts2View™ online database at the conclusion of the symposium.
About BostonGene Corporation
BostonGene's mission is to power healthcare's transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
Contacts
Media:
BostonGene
Erin O'Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- Olga Torres Named Top Advisor by Foreign Investment Watch
- Benchmark International Scsflly Fclitd The Trnstn Btw Bagel King Wholesale and Austin Circle Partner
- Attorney Steve Hilst Named Partner at Bisnar Chase
- 26 Provider Fairview Community Health Center Transitions to Intelligent eClinicalWorks Cloud
- New xBit Digital Case Management Feature Saves Examiners Hours of Required Report Upload Time
- Knobull Helps Professionals Fight Personal Isolation At School & Work
- IntellaTriage Hires New Vice President of Technology
- ASI Hosts 2023 Executive Summit for Partners and Announces Annual Award Winners
- Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
- Namify's Website Name Generator: The Ultimate Solution for Finding Your Perfect Website Name
- NFL Quarterback Lamar Jackson & Lamar Jackson Entertainment Presents Roll With The Punches 'It's Okay Knot To Be Okay' Black Tie & Sneaker Gala
- Tuani Lash Brings Luxury Lash Services and Joy to Oakland's Homeless Community
- Massachusetts: Governor Healey Signs $389 Million Supplemental Budget
- Sherry Orel Joins STS Capital Partners
- Boston: City Council Recognizes International Cape Verdean Women's Day
- American Equus Expands Product Line with Suomy Riding Helmets
- "Third Thursdays": w/former Ornette Coleman colleagues joining host Dave Bryant in April & May 2023
- Arbutus Medical Launches TrakPak® with QuikBow™ to Improve Skeletal Traction, Announces Successful Cases
- Axis Communications Unveils New Devices at ISC West, Underscoring Its Commitment to Deep Learning and Advanced Analytics
- Healey-Driscoll Administration Announces Funding for 450 New Affordable Housing Units Across Massachusetts